Results 171 to 180 of about 10,318 (317)
#1700 Heterogeneity in characteristics of target population and definitions of renal outcome on evaluating the renoprotective effect of GLP-1RA in patients with diabetes: a systematic review and meta-analysis of observational studies versus randomized controlled trials [PDF]
Xiaoyu Wu +5 more
openalex +1 more source
GLP‐1RAs and cardiovascular risk reduction in psoriasis: A retrospective cohort study
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Elaine J. Ma +9 more
wiley +1 more source
Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK [PDF]
, 2017 core +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4706-4717, June 2026.ABSTRACT Aim To characterise the metabolic benefits of a GLP‐1/apelin hybrid peptide, namely exendin‐4‐linker‐apelin (ELA), and associated acylated forms, including ELA‐Lys12(γGluPal), ELA‐Lys27(γGluPal) and ELA‐Lys38(γGluPal). Methods Concentration‐ and receptor‐dependent effects of the peptides on insulin secretion and beta‐cell turnover were ...
Ananyaa Sridhar +5 more
wiley +1 more source
Association of GLP‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program
Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4837-4846, June 2026.ABSTRACT Aims To evaluate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation and the risk of hepatic decompensation compared with dipeptidyl peptidase 4 inhibitors (DPP4is) in a racially and ethnically diverse cohort of adults with Type 2 diabetes.
Inyoung Hwang, Yun Kim, Sang Won Lee
wiley +1 more source
Diabetes, Metabolic Syndrome and Obesity, 2015 Leigh MacConell,1 Kate Gurney,2 Jaret Malloy,1 Ming Zhou,3 Orville Kolterman4 1Clinical Development, Bristol-Myers Squibb, San Diego, CA, USA; 2Medical Writing, Bristol-Myers Squibb, San Diego, CA, USA; 3Biostatistics, Bristol-Myers Squibb, Princeton, NJ,
MacConell L +4 more
doaj
Pregnancy Outcomes After Glp-1 Receptor Agonist Exposure And Ethical Considerations [PDF]
The objective of this study is 1) to understand the effect of GLP-1 receptor agonist (GLP-1RA) use in the year prior to conception on risk of developing hypertensive disorders of pregnancy (HDP) and on gestational weight gain (GWG), and 2) to analyze ...
Pondugula, Nishita
core +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4602-4609, June 2026.ABSTRACT Background Although semaglutide 2.4 mg has demonstrated significant weight loss efficacy in clinical trials, real‐world data, particularly with regard to clinically complex and underrepresented populations, remain limited. Objectives The study aims to assess the real‐world effectiveness and patient‐reported outcomes associated with the use of ...
Pierre Bel Lassen +20 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5217-5228, June 2026.ABSTRACT Aims There is ongoing uncertainty about whether initiating sodium–glucose co‐transporter 2 inhibitor (SGLT‐2i) therapy in individuals with type 2 diabetes (T2D) who have elevated baseline HbA1c levels may lead to an additive or potentially synergistic increase in the risk of diabetic ketoacidosis (DKA). This systematic review and meta‐analysis
Samuel Seidu +3 more
wiley +1 more source